Mez

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mez

Overview of Mez

Mez is a therapeutic agent belonging to the class of medications known as aminosalicylates. It is primarily utilized in the management of inflammatory bowel disease (IBD), specifically targeting conditions such as ulcerative colitis. The medication is designed to act locally on the lining of the colon to reduce inflammation and manage symptoms associated with active disease or to help maintain periods of remission.

Mechanism of Action

While the exact process is not fully understood, Mez is believed to work by inhibiting the production of certain substances in the body that cause inflammation. By modulating the inflammatory response within the gastrointestinal tract, the medication helps to decrease swelling and tissue damage in the rectal and colonic mucosa. This localized effect is a key characteristic of its therapeutic application.

Clinical Applications

Mez is commonly indicated for the following situations:

  • Induction of Remission: Used during active flare-ups of mild to moderate ulcerative colitis to reduce symptoms such as abdominal pain, urgency, and rectal bleeding.
  • Maintenance of Remission: Used as a long-term strategy to prevent the recurrence of inflammatory symptoms once the disease is under control.

Common Forms

The medication is available in several formulations to ensure the active ingredient reaches the specific site of inflammation in the lower intestine. These typically include:

  • Oral Formulations: Delayed-release or extended-release tablets and capsules designed to bypass the stomach and release the medication in the colon.
  • Rectal Formulations: Suppositories, foams, or enemas that provide direct application to the distal colon and rectum.

Important Considerations

As with any long-term therapy for chronic inflammatory conditions, the use of Mez involves regular monitoring. Individuals with a known sensitivity to salicylates (such as aspirin) or those with pre-existing kidney or liver conditions generally require careful evaluation before starting treatment. The choice of formulation often depends on the extent and location of the inflammation within the bowel.

Regulatory References

  1. Metronidazole - StatPearls - NCBI Bookshelf

What side effects are possible with Mez?

Possible Side Effects and Safety Information

The safety profile of Mez (Metronidazole) is officially documented by government regulatory bodies, including the FDA and the EMA, and includes categorizations of adverse reactions by frequency and physiological system.

Adverse Reaction Classifications

Side effects are most frequently associated with the Gastrointestinal Disorders and Nervous System Disorders organ classes. Common reactions (affecting 1 in 100 to 1 in 10 people) typically include nausea, abdominal cramping, headache, and an unpleasant metallic taste in the mouth. Reactions such as neutropenia, encephalopathy, and subacute cerebellar syndrome are classified as Very Rare (affecting less than 1 in 10,000 people) or Not Known in frequency.

Serious Adverse Reactions and Systemic Effects

Official labeling highlights the potential for Serious Adverse Reactions, including severe neurological disturbances such as convulsive seizures, encephalopathy, and optic neuropathy. Severe cutaneous reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also documented. Prolonged or repeated courses of therapy are associated with the potential for peripheral neuropathy and leucopenia.

Population-Specific Constraints

Specific safety constraints are mandated for certain patient groups. The drug is contraindicated in patients with Cockayne Syndrome due to the risk of severe, irreversible, and potentially fatal acute hepatic failure. Caution and monitoring for adverse events are specifically advised for patients with severe hepatic impairment or renal impairment, as clearance may be affected. The use of alcohol and Disulfiram is explicitly restricted during and immediately after therapy due to the potential for severe adverse interactions.

Overdose and Emergency Response

Mez Overdose and when to seek help

Overdose Scope

Element Official Regulatory Statement
Documented overdose presentations: Nausea, vomiting, and ataxia.
Physiological systems affected: Central Nervous System (CNS) and Gastrointestinal System.
Population-specific overdose notes: Patients with severe hepatic impairment or end-stage renal disease should be monitored for adverse events due to slower drug or metabolite elimination, increasing the risk of accumulation.
Emergency-response statements: Management of the patient should consist of symptomatic and supportive therapy.

Overdose Classifications

Element Official Regulatory Statement
Severity classification: Manifestations range from common gastrointestinal upset to severe, potentially persistent CNS effects including convulsive seizures and encephalopathy.
Antidote context: No specific antidote is known for Metronidazole overexposure.

Resulting Overdose Structure

Official overdose statements:

  • Acute overdosage is officially documented to present with gastrointestinal distress, specifically nausea and vomiting, and neurological signs such as ataxia.
  • Severe manifestations associated with overexposure include convulsive seizures, encephalopathy, and symptoms of peripheral neuropathy (e.g., numbness or paresthesia).
  • The occurrence of these severe neurological signs requires prompt evaluation and indicates when urgent medical help must be sought.
  • Regulators mandate that patient management in the event of overexposure consists solely of symptomatic and supportive therapy.

Connection to the overall overdose profile (2–4 sentences):

Regulatory documents define the overdose profile by listing severe CNS manifestations that may follow overexposure. This profile is constrained by the official statement that no specific antidote is known, thus mandating a clinical response centered entirely on symptomatic and supportive therapy to manage the officially documented signs.

Therapeutic Uses of Mez

What Mez Treats: Main Uses and Benefits

Mez is commonly used in situations involving certain distressing symptoms to help manage certain conditions that present with disruptive symptom manifestations. It is applied across domains where additional symptomatic support is needed in relation to these conditions. It helps address symptomatic discomfort and provides supportive relief when symptoms become temporarily overwhelming.


Managing Acute and Episodic Symptoms

Mez is generally used across conditions presenting with acute episodes. It supports patients during difficult episodes by easing distress and contributes to improved comfort during symptomatic periods. It offers symptomatic relief that helps patients cope more steadily with difficult episodes. It is relevant in situations involving recurrent or episodic manifestations.

Quick Fact: Support for Acute Discomfort
Assists with maintaining functional stability when symptoms become more noticeable.

Addressing Disruptive Symptom Clusters

This medicine is relevant in contexts marked by increased discomfort or tension where the symptoms create noticeable physiological strain. Mez is used when groups of symptoms appear suddenly or fluctuate and interfere with daily comfort, providing supportive relief when the underlying condition requires additional symptomatic support.

Eligibility and Restrictions for Use

Official Eligibility for Metronidazole (Mez)

The ability to use Mez is determined by specific exclusions and population restrictions detailed in regulatory documents.

Contraindicated Populations Must Not Use
Hypersensitivity Known allergy to metronidazole or other nitroimidazole derivatives
Cockayne Syndrome Patients with this condition due to risk of fatal hepatotoxicity
Disulfiram/Alcohol Use Within the last two weeks, or with concurrent use of alcohol or propylene glycol

Age and Reproductive Status: The medicine is generally eligible for use in adults and most children. However, use is often not recommended during the first trimester of pregnancy for certain indications. During lactation, a specific recommendation exists to discontinue breastfeeding for 12–24 hours following a single, high dose to reduce infant exposure.

Condition-Based Restrictions: Patients with severe hepatic impairment (Child-Pugh C) require a reduced dose because the drug is metabolized slowly, leading to accumulation. Patients with end-stage renal disease (ESRD) and the elderly are officially recommended to undergo monitoring for accumulation and adverse events. Use requires caution in those with a history of certain CNS disorders or blood dyscrasias.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Mesalamine (Mez) has documented interactions with specific drug classes and agents, primarily affecting blood cell production and kidney function. These interactions are based on official regulatory labeling.

Interacting Product Category Potential Effect and Requirement
Thiopurines (e.g., Azathioprine, 6-Mercaptopurine) Increased risk of myelosuppression (blood disorders/blood dyscrasias). Monitoring of complete blood cell counts and platelet counts is required.
Nephrotoxic Agents (including NSAIDs) Increased risk of nephrotoxicity (kidney-related adverse reactions). Renal function must be monitored closely during co-administration.
Coumarin-type Anticoagulants (e.g., Warfarin) Possible potentiation of the anticoagulant effect, increasing the risk of bleeding. The anticoagulant effect may be increased or decreased; close monitoring is necessary.
Lactulose or similar preparations May affect the drug's release mechanism by lowering the pH in the colon, potentially reducing mesalamine's efficacy.

Combinations with Glucocorticoids may increase undesirable gastric effects. Mesalamine is a salicylate, and therefore, other typical salicylate interactions, such as those with Methotrexate, Probenecid, and some diuretics (e.g., Spironolactone), are possible.

Mechanism of Action

The mechanism of metronidazole's action is defined by its ability to become a highly reactive, cytotoxic agent only after encountering the unique internal conditions of its target organisms.


Enzymatic Bioactivation and Targeted Selectivity

This domain covers the process by which the drug, which is initially an inactive prodrug, is activated. The transformation is catalyzed by specific nitroreductase enzymes and facilitated by the low-redox potential found within anaerobic and microaerophilic cells. This conditional activation results in the highly selective formation of a cytotoxic nitro-radical anion, a process mediated by the pathogen's unique low-redox environment.


Irreversible Genomic Disruption

This domain explains the final outcome of the active drug. The generated nitro-radical anion intermediate chemically reacts with the pathogen’s DNA, causing irreversible strand breakage and disrupting the genetic helix. This physical destruction of the genome halts all essential cellular functions, establishing a cidal effect that leads to the reduction of the pathogenic microbial load from the affected physiological system.

Dosage and Administration Information

How Mez Is Used: Official Administration Guidelines

Metronidazole, the active ingredient in Mez, is administered through diverse routes depending on the treatment context, including Oral intake, Intravenous (IV) Infusion, and Topical/Local application.

For systemic infections, dosing involves calculated regimens, often beginning with an IV loading dose of 15 mg/kg followed by a maintenance dose of 7.5 mg/kg (e.g., 500 mg) administered on a frequent schedule, typically every 6 or 8 hours. The duration of therapy for acute systemic conditions is commonly 7 to 10 days, though a single 2 g dose is approved for certain specific indications. The maximum daily adult dose should not exceed 4 g across all routes.

Administration Conditions and Population Adjustments

Procedural Requirement Official Instruction
Oral Intake Timing May be taken with or after food to enhance gastrointestinal tolerance.
IV Administration Must be given via slow infusion over 30 to 60 minutes; IV solutions should not be used in series connections.
Hepatic Impairment Patients with severe hepatic impairment may require a dose reduction of up to 50%.
Missed Doses Take the dose as soon as remembered unless close to the next scheduled dose, in which case the missed dose is skipped. Do not double the dose.

These official instructions define a structured approach to use, ensuring the drug is delivered via the correct route, at the calculated dose and frequency, and under specific procedural constraints.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mez

The research base for Metronidazole (Mez) includes clinical research such as randomized controlled trials and large-scale reviews. This evidence was applied in studies examining the drug's use for specific types of bacterial and parasitic organisms. Findings describe group patterns observed in the studies; research provides context but not individual predictions.


Evidence for Use in Systemic Anaerobic Bacterial Infections

Research has extensively examined the use of Metronidazole in patients with infections caused by oxygen-sensitive (anaerobic) bacteria. Studies monitored outcomes such as the status of clinical clearance and the subsequent requirement for changes in the antibiotic treatment protocol. Studies reported measurements related to the status of clinical clearance across various types of anaerobic pathogens in the observed populations. What remains uncertain is the status of long-term patient outcomes across a diverse set of infection sites, and data are still emerging regarding optimal dosing adjustments for patients with specific health conditions.


Research on Treating Specific Protozoal and Complex Infections

Metronidazole was studied for use in a specific range of conditions characterized by fluctuating or episodic manifestations.

Research on Trichomoniasis and Amebiasis

For both Trichomoniasis (a parasitic infection) and Amebiasis, research explored short-term symptom changes, primarily using Clinical Trials to assess the status of parasitic clearance from the body. Trials consistently reported measurements related to the status of parasite clearance. The research base for Amebiasis suggests that new evidence for this indication is limited to treatment comparisons or observational data, as few recent, large-scale, placebo-controlled RCTs are available.

Research on Bacterial Vaginosis (BV)

Studies for Bacterial Vaginosis examined both oral and topical preparations of the drug, often using Randomized Placebo-Controlled Trials. Studies reported measurements related to the initial status of clinical clearance. However, research highlights that studies consistently described patterns of recurrence observed at follow-up assessments over several months. This means there is limited information for long-term outcomes regarding the sustained maintenance of symptom control.


Evidence in Special Patient Populations

Research has explored the use of Metronidazole in various special populations. Studies have examined cohorts of children (pediatric patients) and older adults. Furthermore, research examined patients with severe hepatic (liver) or renal (kidney) impairment. Findings describe group patterns related to how the drug concentrations evolved in these special patient groups, but results apply only to the populations studied.

Key Studies & References

  1. Metronidazole Drug Profile (NIH StatPearls)
  2. Topical Metronidazole for Rosacea: A Review of the Evidence
  3. Guidelines for the Prevention and Treatment of Surgical Site Infection (SSI)

Frequently Asked Questions (FAQ)

Common questions about Mez (FAQ)


Q: How quickly does Mez start working after you take it?

According to official product information, when taken orally, the medication is generally well-absorbed into the bloodstream. The peak plasma concentrations, which is the highest level of the medicine in the blood, typically occur relatively quickly, often between one and two hours after the dose is taken.


Q: Can Mez cause changes in mood or anxiety?

Official warnings note that Mez is associated with Nervous System Disorders and, in rare cases, severe neurological events like encephalopathy or seizures. While specific changes in mood or anxiety may not be commonly listed, official documentation indicates that caution is generally advised for patients with a history of CNS disorders (Central Nervous System problems).


Q: Does Mez cause weight gain or loss?

Official product labeling does not typically list significant weight changes as a frequent side effect of Mez. However, in less common reports of adverse events, weight loss has been noted. If an unexpected change in weight is noticed while using this medication, it is appropriate to discuss this with a healthcare provider.


Q: Is it safe to take over-the-counter pain relievers like ibuprofen with Mez?

Official drug interaction information advises caution when taking Mez with Nephrotoxic Agents, which include Nonsteroidal Anti-inflammatory Drugs (NSAIDs) like ibuprofen. This combination may increase the risk of nephrotoxicity, a type of kidney-related adverse reaction. Official prescribing information notes that monitoring of renal function (kidney health) is typically recommended when these medications are co-administered.


Q: How long can someone safely stay on Mez?

Mez is primarily intended for short-term treatment; the duration of therapy for acute conditions is commonly 7 to 10 days. Regulatory warnings indicate that prolonged or repeated courses of therapy carry a potential risk for the development of peripheral neuropathy (nerve damage) and leucopenia (a low white blood cell count). Decisions regarding extended use beyond the typical course should be made based on individual clinical evaluation.


Q: Does taking Mez require regular blood tests?

Official information indicates that monitoring of complete blood cell counts may be recommended before and after treatment, especially for patients with a history of blood disorders or those receiving repeated courses. This precaution is also noted when the drug is combined with certain interacting medications, like thiopurines.


Q: Can I crush or split the Mez tablet if I have trouble swallowing pills?

The official product label does not specifically instruct patients to crush or split tablets. Altering the form of a medication can sometimes affect how it is absorbed or released in the body. Tablets should generally not be split or crushed unless the specific product label or a healthcare professional has confirmed that this is permissible.


Q: What type of condition does Mez treat in children?

Official prescribing information indicates that Mez is used in pediatric patients for the treatment of specific infections. This includes certain anaerobic bacterial infections and some protozoal infections such as amebiasis and trichomoniasis, depending on the specific product's regulatory label.


Q: Is it normal to feel a little dizzy when starting Mez?

Official patient information indicates that dizziness or lightheadedness is listed as a less common, but possible, side effect of the medication. If dizziness is experienced and is severe or concerning, a healthcare provider should be contacted.


Q: Is Mez safe for older adults (seniors)?

Mez is generally eligible for use in geriatric patients. However, regulatory authorities recommend monitoring for adverse events in the elderly population. This is due to the potential for higher levels of the active medication metabolite in the body, even when kidney and liver function appear normal.


Q: Can Mez cause long-term side effects?

Yes, official warnings confirm that taking the medication in prolonged or repeated courses has been associated with potential long-term risks. These include the development of peripheral neuropathy (a type of nerve damage) and changes in blood counts like leucopenia.


Q: Does Mez interact with birth control pills?

According to official data, the effectiveness of estrogen and progestin hormones used for oral contraception may be reduced while using Mez. Patients using hormonal contraceptives are typically advised to discuss their birth control method with a healthcare provider during treatment.


Q: Is there a generic version of Mez available?

Yes, regulatory databases confirm that the active ingredient, Metronidazole, is available from various manufacturers as a therapeutically equivalent and FDA-approved generic product.


Q: What are common patient experiences when first starting Mez?

The most common initial side effects, affecting between 1 in 100 and 1 in 10 people, include nausea, abdominal cramping, headache, and a noticeable metallic taste in the mouth. These effects are often most noticeable when therapy is first initiated.


Q: Why do some people feel nauseous when they take Mez?

Nausea is a very common side effect, likely due to the medicine's effect on the gastrointestinal system. Official administration guidelines mention that taking the medication with or immediately after food can help to enhance gastrointestinal tolerance and potentially reduce feelings of nausea or upset stomach.


Q: Can Mez be used for short-term problems or is it for chronic conditions?

The drug is primarily indicated for short-term treatment of specific acute infections, with most courses of therapy lasting 7 to 10 days. Use for certain chronic conditions is limited and requires specialized monitoring due to the potential for long-term side effects.


Q: Is it possible to develop a tolerance to Mez over time?

Official labeling notes that there is a potential for the development of resistance against metronidazole in the target organisms, such as bacteria or parasites. This resistance can develop through various mechanisms, which may affect the overall effectiveness of the treatment over time.


Q: Does Mez have a strong smell or taste?

A sharp, unpleasant, metallic taste in the mouth is documented as a very common side effect of the medication. This taste is one of the most frequently reported adverse reactions by patients.


Q: Does my diet affect how well Mez is absorbed?

Pharmacokinetic studies indicate that taking the medicine with food may slow down the rate of drug absorption into the bloodstream. However, food does not typically diminish the overall amount of drug that is eventually absorbed.


Q: Is it true that Mez can change the color of my urine?

Yes, official patient information states that Mez may cause urine to become darker or have a reddish-brown color. This is considered a common and generally harmless effect that is not usually a cause for immediate medical concern.


Q: Are there any age restrictions for using Mez?

The drug is contraindicated (must not be used) in infants who have been diagnosed with Cockayne Syndrome due to the risk of fatal liver failure. For other infants and children, use during the first few months of life is sometimes restricted due to a diminished capacity to eliminate the drug.


Q: What happens if I accidentally take two doses of Mez close together?

Official guidelines for a missed dose explicitly advise not to take a double dose to make up for it. In the event of a suspected overdose, official labeling recommends seeking immediate medical evaluation.


Q: Why is Mez sometimes used with another medication?

Regulatory indications state that Mez is often used in combination with other antimicrobial agents. This approach is frequently necessary when treating mixed aerobic and anaerobic infections or for specific procedures like post-surgical treatments and certain regimens targeting H. pylori.


Q: Is it better to take Mez in the morning or at night?

Dosing is typically specified as a frequent, scheduled regimen (e.g., every 6 or 8 hours) to maintain consistent blood levels. The only official instruction regarding timing is that it may be taken with or after food to improve gastrointestinal tolerance, rather than a preference for morning or night.


Q: What if I experience unusual swelling while taking Mez?

Regulatory documents advise patients to be alert for signs of hypersensitivity reactions or severe cutaneous adverse reactions. Symptoms like unusual swelling (e.g., of the face, lips, or tongue), hives, rash, or blistering may indicate a serious reaction. These symptoms are typically noted as requiring prompt medical evaluation.

How should Mez be stored and disposed of?

Official Storage and Disposal Requirements

Metronidazole (Mez) must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with protection from brief temperature excursions. The medicine must be kept protected from light, moisture, and excess heat, and should not be allowed to freeze.

Storage Requirement Condition
Temperature Controlled room temperature
Protection Keep from light, moisture, and freezing
Container Keep in original, tightly closed container

For safety, the container must be kept out of the sight and reach of children and sealed with a child-resistant closure. Unused or expired medication must be disposed of according to local, regional, and national regulations. The product should not be released into the environment or flushed into sewer systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mez found in:

A-Z Index: